Om1 and medtronic partner on propel study to assess long-term outcomes for patients with chronic rhinosinusitis

Boston--(business wire)--om1, the leading ai and insights-driven technology and data company specializing in personalized medicine, evidence generation, and real-world evidence, today announced results from its partnership with medtronic to investigate the propeltm family of devices – corticosteroid-eluting, bioabsorbable implants. the study focused on healthcare resource use (hcru) and long-term outcomes in patients with chronic rhinosinusitis (crs) who underwent endoscopic sinus surgery (ess).
MDT Ratings Summary
MDT Quant Ranking